基于猪圆环病毒2a或2b型的实验性疫苗对PCV2d/猪细小病毒2型共攻击提供保护
研究评估两种相似工艺生产的PCV2疫苗(分别含PCV2a或PCV2b衣壳)在常规猪模型中对抗PCV2d/PPV2共攻击的效力。60头3周龄猪随机分为不接种组、VAC2a组和VAC2b组,每组20头,4周龄和6周龄接种,8周龄攻击。两种疫苗均诱导了更高的体液和细胞免疫,并减少了PCV2d病毒血症和PCV2相关病理病变。
要点
- PCV2a和PCV2b疫苗均诱导了针对PCV2d/PPV2共攻击的免疫反应和临床保护。
- 接种疫苗组(无论基因型)在攻击前外周血单核细胞经PCV2d刺激后干扰素γ分泌细胞数显著高于未接种攻击对照组。
- 两种疫苗均降低了PCV2d病毒血症和PCV2相关病理病变。
核心结论
- 在本研究条件下,PCV2a和PCV2b疫苗制剂各自诱导了针对异源PCV2d/PPV2共攻击的免疫反应和临床保护。
研究设计与样本
- 60头3周龄猪来自PCV2血清阳性但无活动性病毒复制证据的农场,按PCV2抗体滴度区组后随机分为三组,每组20头:不接种组(攻击对照)、PCV2a疫苗接种组(VAC2a)和PCV2b疫苗接种组(VAC2b)。
主要发现
- 接种疫苗组(无论PCV2基因型)在攻击前外周血单核细胞经PCV2d刺激后干扰素γ分泌细胞数显著高于未接种攻击对照组;PCV2a和PCV2b疫苗接种均减少了PCV2d病毒血症和PCV2相关病理病变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
With the discovery of Porcine circovirus type 2d (PCV2d) in the USA in 2012 and subsequent genotype shift from the previously predominant PCV2b to PCV2d in the face of widespread PCV2a vaccination, concerns over PCV2 vaccine efficacy were raised. The objective of this study was to evaluate the efficacy of two similarly produced PCV2 vaccines, one containing the PCV2a capsid and the other one containing the PCV2b capsid, in the conventional pig model against PCV2d/porcine parvovirus 2 (PPV2) co-challenge. A co-challenge was added since there is evidence that PPV2 may exacerbate PCV2 infection and since PCV2 only rarely causes disease in experimentally infected pigs, hence vaccine efficacy can be difficult to assess. In brief, sixty 3-week-old-pigs from a PCV2 seropositive farm without evidence of active virus replication (no PCV2 viremia, low antibody titers with no evidence of increase after two consecutive bleedings) were blocked by PCV2 antibody titer and then randomly divided into three groups with 20 pigs each, a non-vaccinated group (challenge control), a PCV2a vaccinated group (VAC2a) and a PCV2b vaccinated group (VAC2b). Vaccinations were done at 4 and again at 6 weeks of age. At 8 weeks of age, all pigs were challenged with a PCV2d strain via intranasal and intramuscular routes of inoculation followed by intramuscular administration of PPV2 one day later. PCV2 vaccination, regardless of PCV2 genotype, resulted in significantly higher humoral and cellular immunity compared to non-vaccinated challenge control pigs as evidenced by increased numbers of interferon (IFN) γ secreting cells after PCV2d stimulation of peripheral blood mononuclear cells collected prior to challenge. Furthermore, PCV2a and PCV2b vaccinations both reduced PCV2d viremia and PCV2-associated pathological lesions. Under the study conditions, the PCV2a and PCV2b vaccine preparations each induced immune responses and clinical protection against a heterologous PCV2d/PPV2 co-challenge.
引用
- Opriessnig T, Karuppannan AK, Halbur PG, et al. Porcine circovirus type 2a or 2b based experimental vaccines provide protection against PCV2d/porcine parvovirus 2 co-challenge. Vaccine. 2020. PMID: 31974016. doi:10.1016/j.vaccine.2020.01.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。